Fidaxomicin inhibits Clostridium difficile toxin a-mediated enteritis in the mouse ileum

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4642-4650

  Koon, Hon Wai ^a   Ho, Samantha ^a   Hing, Tressia C ^a   Cheng, Michelle ^a   Chen, Xinhua ^b   Ichikawa, Yoshi ^c   Kelly, Ciarán P ^b   Pothoulakis, Charalabos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BACTERIAL TOXIN; ENTEROTOXIN; FIDAXOMICIN; INTERLEUKIN 1BETA; MESSENGER RNA; METRONIDAZOLE; OP-1118; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; VANCOMYCIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; EDEMA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION; GENETICS; ILEUM; INTESTINE MUCOSA; INTRALESIONAL DRUG ADMINISTRATION; MALE; METABOLISM; MICROBIOLOGY; MOUSE; NEUTROPHIL CHEMOTAXIS; PATHOGENICITY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; EDEMA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION; ILEUM; INJECTIONS, INTRALESIONAL; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; METRONIDAZOLE; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; RNA, MESSENGER; VANCOMYCIN;

EID: 84905400614     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02783-14     Document Type: Article

References (42)

1. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:1932-1940. http://dx.doi.org/10.1056/NEJMra0707500.
2. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. http://dx.doi.org/10.1038/nature09397.
3. Dupont HL. 2013. Diagnosis and management of Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 11:1216-1223. http://dx.doi.org/10. 1016/j.cgh.2013.03.016.
4. Johnson S. 2009. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J. Infect. 58:403-410. http://dx.doi.org/10.1016/j.jinf.2009.03.010.
5. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12:281-289. http://dx.doi.org/10.1016/S1473-3099(11)70374-7.
6. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE. 2012. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55(Suppl 2):S93-S103. http://dx.doi.org/10.1093/cid/cis499.
7. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431. http://dx.doi.org/10.1056/ NEJMoa0910812.
8. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 56:2493-2503. http://dx.doi.org/10.1128/AAC.06305-11.
9. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. 2011. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob. Agents Chemother. 55:5194-5199. http://dx.doi.org/10.1128/AAC.00625-11.
10. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719. http://dx.doi.org/10.1128/AAC.01623-06.
11. Artsimovitch I, Seddon J, Sears P. 2012. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 55(Suppl 2):S127-S131. http://dx.doi.org/10.1093/cid/cis358.
12. Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. 2013. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68:515-522. http://dx.doi.org/10.1093/jac/dks450.
13. Duggan ST. 2011. Fidaxomicin: in Clostridium difficile infection. Drugs 71:2445-2456. http://dx.doi.org/10.2165/11208220-000000000-00000.
14. Amado-Rodriguez L, Gonzalez-Lopez A, Lopez-Alonso I, Aguirre A, Astudillo A, Batalla-Solis E, Blazquez-Prieto J, Garcia-Prieto E, Albaiceta GM. 2013. Anti-inflammatory effects of clarithromycin in ventilatorinduced lung injury. Respir. Res. 14:52. http://dx.doi.org/10.1186/1465-9921-14-52.
15. Fernandez-Robredo P, Recalde S, Moreno-Orduna M, Garcia-Garcia L, Zarranz-Ventura J, Garcia-Layana A. 2013. Azithromycin reduces inflammation in a rat model of acute conjunctivitis. Mol. Vis. 19:153-165.
16. Hing TC, Ho S, Shih DQ, Ichikawa R, Cheng M, Chen J, Chen X, Law I, Najarian R, Kelly CP, Gallo RL, Targan SR, Pothoulakis C, Koon HW. 2013. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut 62:1295-1305. http://dx.doi.org/10.1136/gutjnl-2012-302180.
17. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O'Keane JC, Snider RM, Leeman SE. 1994. CP-96, 345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc. Natl. Acad. Sci. U. S. A. 91:947-951. http://dx.doi.org/10.1073/pnas.91.3. 947.
18. O'Horo JC, Jindai K, Kunzer B, Safdar N. 2014. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 42:43-59. http://dx.doi.org/10.1007/s15010-013-0496-x.
19. Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X, Kelly CP, Targan SR, Pothoulakis C. 2013. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob. Agents Chemother. 57:3214-3223. http://dx.doi.org/10.1128/AAC.02633-12.
20. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4:719-722.
21. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O'Brien M, Pothoulakis C, Kelly CP. 2006. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J. Biol. Chem. 281:24449-24454. http://dx.doi.org/10.1074/jbc.M605200200.
22. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP. 2000. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 105:1147-1156. http://dx.doi.org/10.1172/JCI7545.
23. Gerding DN, Johnson S. 2011. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. Nat. Rev. Gastroenterol. Hepatol. 8:67-68. http://dx.doi.org/10.1038/nrgastro.2010.215.
24. Golan Y, Epstein L. 2012. Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea. Therap. Adv. Gastroenterol. 5:395-402. http://dx.doi.org/10.1177/1756283X12461294.
25. Hardesty JS, Juang P. 2011. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. Pharmacotherapy 31:877-886. http://dx.doi.org/10.1592/phco.31.9.877.
26. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin. Infect. Dis. 55(Suppl 2):S132-S142. http://dx.doi.org/10.1093/cid/cis338.
27. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficileinfected patients than does vancomycin. Microbiology 156:3354-3359. http://dx.doi.org/10.1099/mic. 0.042010-0.
28. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. 2012. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55(Suppl 2):S162-S169. http://dx.doi.org/10.1093/cid/cis453.
29. Best EL, Freeman J, Wilcox MH. 2012. Models for the study of Clostridium difficile infection. Gut Microbes 3:145-167. http://dx.doi.org/10.4161/gmic. 19526.
30. Pothoulakis C. 2000. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. N. Y. Acad. Sci. 915:347-356. http://dx.doi.org/ 10.1111/j.1749-6632.2000.tb05263.x.
31. Pothoulakis C, Lamont JT. 2001. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. II. The integrated response of the intestine to Clostridium difficile toxins. Am. J. Physiol. Gastrointest. Liver Physiol. 280:G178-G183.
32. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420. http://dx.doi.org/10.1016/S0016-5085(03)00902-8.
33. Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA. 2008. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52:1391-1395. http://dx.doi.org/10.1128/AAC.01045-07.
34. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. 2012. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J. Antimicrob. Chemother. 67:123-129. http://dx.doi.org/10.1093/jac/dkr417.
35. Sharma-Kuinkel BK, Zhang Y, Yan Q, Ahn SH, Fowler VG, Jr. 2013. Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. PLoS One 8:e60463. http://dx.doi.org/10.1371/journal.pone. 0060463.
36. Rizzo A, Paolillo R, Guida L, Annunziata M, Bevilacqua N, Tufano MA. 2010. Effect of metronidazole and modulation of cytokine production on human periodontal ligament cells. Int. Immunopharmacol. 10:744-750. http://dx.doi.org/10.1016/j.intimp.2010.04.004.
37. Shaddox LM, Goncalves PF, Vovk A, Allin N, Huang H, Hou W, Aukhil I, Wallet SM. 2013. LPS-induced inflammatory response after therapy of aggressive periodontitis. J. Dent. Res. 92:702-708. http://dx.doi.org/10.1177/ 0022034513495242.
38. Na X, Zhao D, Koon HW, Kim H, Husmark J, Moyer MP, Pothoulakis C, LaMont JT. 2005. Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 128:1002-1011. http://dx.doi.org/10.1053/j.gastro.2005.01.053.
39. Hiwatashi Y, Maeda M, Fukushima H, Onda K, Tanaka S, Utsumi H, Hirano T. 2011. Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen. J. Pharm. Pharmacol. 63:1320-1326. http://dx.doi.org/10.1111/j.2042-7158.2011.01343.x.
40. Shinkai M, Foster GH, Rubin BK. 2006. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 290:L75-L85. http://dx.doi.org/10.1152/ajplung.00093.2005.
41. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M. 2000. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292:156-163.
42. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK. 2012. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 3:121-134. http://dx.doi.org/10.4161/gmic.19399.